Patent ID: 11860163
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  G

Claim 11:
12. The method of claim 11, wherein:
(a) (i) the subject is identified as likely to have a response to the CAR T cell therapy, if the level of the bacterium or spores thereof is lower than the reference bacterium or spores thereof level; or (ii) the subject is identified as likely to have no response or a poor response to the CAR T cell therapy, if the level of the bacterium or spores thereof is higher than the reference bacterium or spores thereof level,
wherein the bacterium is selected from the group consisting of bacteria of the Peptostreptococcaceae family, bacteria of the Bacteroidaceae family, bacteria of the Clostridiaceae family, and any combinations thereof; and/or

(b) (i) the subject is identified as likely to have a response to the CAR T cell therapy, if the level of the bacterium or spores thereof is higher than the reference bacterium or spores thereof level; or (ii) the subject is identified as likely to have no response or a poor response to the CAR T cell therapy, if the level of the bacterium or spores thereof is lower than the reference bacterium or spores thereof level,
wherein the bacterium is selected from the group consisting of bacteria of the Lachnospiraceae family, bacteria of the Rikenellaceae family, bacteria of the Lactobacillaceae family, bacteria of the Oscillospiraceae family, bacteria of the Ruminococcaceae family, bacteria of the Acidaminococcaceae family, bacteria of the Clostridiaceae family, bacteria of the Peptococcaceae family and any combinations thereof.